Cargando…

Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non‐squamous non‐small cell lung cancer patients

PURPOSE: The relationship between mutant KRAS and the risk of disease progression and death in advanced non‐squamous non‐small cell lung cancer (NSCLC) is still controversial among current studies, and the effects of distinct KRAS mutations on prognosis may be different. This study aimed to further...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Feiwen, Wang, Fang, He, Jianbo, Zhou, Shaozhang, Luo, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315828/ https://www.ncbi.nlm.nih.gov/pubmed/37140194 http://dx.doi.org/10.1002/cam4.5995

Ejemplares similares

The prevalence and prognostic value of KRAS co‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients
por: Cai, Dongjing, et al.
Publicado: (2019)

The predictive value of pretreatment haemoglobin-to-red cell distribution width ratio for overall survival of patients with advanced non-small cell lung cancer: a propensity score matching analysis
por: Jiang*, Huiqin, et al.
Publicado: (2021)

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
por: Judd, Julia, et al.
Publicado: (2021)

The Association between Pretreatment anemia and Overall Survival in Advanced Non-small Cell lung Cancer: A Retrospective Cohort Study Using Propensity Score Matching
por: Huang, Yucong, et al.
Publicado: (2022)

A Retrospective Cohort Study on Pretreated Neutrophil-to-Lymphocyte Ratio and Prognosis of Small Cell Lung Cancer: Evidence of Effect Modification by Chemotherapy Regimen
por: Liu, Feiwen, et al.
Publicado: (2020)

A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations
por: Lei, Lei, et al.
Publicado: (2019)

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer
por: Yagishita, Shigehiro, et al.
Publicado: (2015)

Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
por: Cheng, He, et al.
Publicado: (2020)

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
por: Sun, Jong-Mu, et al.
Publicado: (2013)

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2019)

Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer
por: Pan, Mingmei, et al.
Publicado: (2021)

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer
por: Zulato, Elisabetta, et al.
Publicado: (2020)

Realities of KRAS-mutated non-small cell lung cancer
por: Min, Young Joo
Publicado: (2017)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

Pretreatment plasma d-dimer levels as an independent prognostic factor for overall survival among patients with advanced non-small-cell lung cancer
por: Liu, Qianfei, et al.
Publicado: (2020)

Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China
por: Gu, Guomin, et al.
Publicado: (2022)

KRAS and DAXX/ATRX Gene Mutations Are Correlated with the Clinicopathological Features, Advanced Diseases, and Poor Prognosis in Chinese Patients with Pancreatic Neuroendocrine Tumors
por: Yuan, Fei, et al.
Publicado: (2014)

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
por: Jänne, P A, et al.
Publicado: (2015)

Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy
por: Veccia, Antonello, et al.
Publicado: (2022)

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2022)

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
por: O’Sullivan, Éabha, et al.
Publicado: (2023)

The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations
por: Zheng, Difan, et al.
Publicado: (2016)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer
por: Jia, Yijun, et al.
Publicado: (2017)

Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer
por: Kriegshäuser, Gernot, et al.
Publicado: (2011)

Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non‐small cell lung cancer patients
por: Ding, Ying, et al.
Publicado: (2019)

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
por: Marabese, Mirko, et al.
Publicado: (2015)

KRAS Mutations in Squamous Cell Carcinomas of the Lung
por: Acker, Fabian, et al.
Publicado: (2021)

Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients
por: Boldrin, Elisa, et al.
Publicado: (2019)

Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma
por: Parker, Amelia L., et al.
Publicado: (2022)

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
por: Bournet, Barbara, et al.
Publicado: (2016)

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
por: Liu, Si-Yang, et al.
Publicado: (2020)

The Prevalence and Concurrent Pathogenic Mutations of KRAS(G12C) in Northeast Chinese Non-small-cell Lung Cancer Patients
por: Liu, Yan, et al.
Publicado: (2021)

The Effect of PD-1 Inhibitor Combined with Chemotherapy on the Level of Peripheral Blood T Lymphocytes among Patients with Non-Small-Cell Lung Cancer and Its Relationship with Prognosis
por: Zhao, Yun, et al.
Publicado: (2022)

Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis
por: Yuan, Chengliang, et al.
Publicado: (2021)

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
por: Vaclova, Tereza, et al.
Publicado: (2022)

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
por: Reita, Damien, et al.
Publicado: (2022)

KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer
por: Eklund, Ella A., et al.
Publicado: (2022)

Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk
por: Wing, Sam E., et al.
Publicado: (2022)

High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
por: Thomas, Anish, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qt6cu3m93dlvaq48b1arg7s8i5